in january 2015 , we received fda approval to market triferic® our lead branded drug . based on our clinical trial results , we believe triferic® has the potential to capture significant market share due to its unique attributes and clinical benefits , including savings on nursing administration time , potential to reduce expensive esa treatments and excellent safety profile . triferic® has a unique mode of action and has proven to be both safe and effective in iron replacement and maintenance of hemoglobin . in 2015 , we had revenue of $ 55.4 million , an increase of 2.1 % or $ 1.2 million over 2014. all of our revenue in 2014 and nearly all of our revenue in 2015 was from our dialysis concentrate business . we supply approximately 25 % of the united states domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries , primarily in the americas and the pacific rim . we obtained fda approval to market triferic® in january 2015 and commenced our marketing efforts following approval . after building sufficient inventory to support our product launch , we offered triferic® commercially in september 2015. triferic® sales and marketing efforts have been directed to providers controlling the vast majority of dialysis patients . the triferic® sales cycle is progressing in a manner and time frame consistent with the company 's prior experiences with its other product launches in the renal market . several providers have agreed to initiate pilot studies of triferic® and we anticipate these pilot programs will provide the basis for future adoption . triferic® sales in 2015 were not material . our global strategy is to out-license triferic® for key international markets . we are actively pursuing the international development and licensing of triferic® in targeted markets and regions . we recently completed a licensing agreement and product supply agreement for china . we are in discussions and negotiations regarding a number of other significant renal markets . in addition to marketing triferic® , we are working to produce sufficient inventory to begin marketing calcitriol , our generic injectable vitamin-d analogue . we are dependent upon contract manufacturing organizations to manufacture calcitriol for us . we expect to begin marketing calcitriol as soon as inventory levels are at an adequate level to ensure sufficient supply . in october 2014 , we entered into the distribution agreement with baxter , a leading global dialysis products supplier , to exclusively distribute our dialysis concentrates in the united states and certain foreign markets . the distribution agreement does not include our drug products . under the distribution agreement , we are the exclusive third party supplier of dialysis concentrates to baxter in the united states . rockwell receives a pre-defined gross profit margin on its products sold through baxter which adjusts each year over the ten year term of the agreement and is subject to an annual true-up . baxter must achieve certain growth targets to maintain its exclusivity under the agreement . this distribution agreement relates solely to our dialysis concentrate business and excludes any future 34 drug related business . for a more detailed description of the distribution agreement , see `` item 1businessdistribution agreement with baxter . we expect the distribution relationship with baxter under the distribution agreement to have a generally positive impact on our operating profit . our operating costs are expected to decrease and operating income should improve . initially , our sales will decrease , partially offset by the portion of the $ 20 million license fee received from baxter that is being recognized as revenue over the term of the distribution agreement . going forward over time , we expect our overall domestic and global concentrate sales to increase as a result of baxter 's expanded marketing reach , coupled with the anticipated expansion of our manufacturing operations in the western united states . results of operations for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 sales in 2015 , our sales were $ 55.4 million compared to $ 54.2 million in 2014 an increase of $ 1.2 million or 2.1 % . our domestic concentrate business sales increased 4.2 % or $ 1.9 million in 2015 compared to 2014. we launched triferic® in late september 2015 and our net sales of triferic® were $ 0.2 million for 2015. our international concentrate sales increased 1.3 % or $ 0.1 million in 2015 over 2014. our net revenue from third party contract manufacturing decreased $ 1.0 million in 2015 compared to 2014 following cessation of contract manufacturing for a certain non-hemodialysis customer . as a result of our distribution agreement with baxter , all domestic customer contracts for concentrate products that permitted assignment to baxter without consent have been assigned to baxter throughout 2015. baxter subsequently began to invoice those customers following assignment . our 2015 sales largely reflect the lower distributor prices paid by baxter , such that our sales are lower on those accounts billed by baxter than they were historically . our 2015 sales were favorably impacted by the recognition of deferred license revenue under the distribution agreement of $ 2.1 million in 2015 compared to $ 0.5 million in 2014. gross profit our gross profit was $ 8.9 million in 2015 , an increase of $ 0.4 million or 4.6 % compared to 2014. gross profit margins were 16.1 % in 2015 compared to 15.8 % in 2014. gross profit was favorably impacted by recognition of deferred license revenue under the distribution agreement of $ 2.1 million in 2015 compared to $ 0.5 million in 2014. gross profit was negativelyimpacted by lower sales on those accounts billed by baxter following assumption of billing by baxter . story_separator_special_tag changes in estimates are reflected in our financial statements in the period of change based upon on-going actual experience , trends , or subsequent realization depending on the nature and predictability of the estimates and contingencies . interim changes in estimates are generally applied prospectively within annual periods . certain accounting estimates , including those concerning revenue recognition , allowance for doubtful accounts , impairments of long-lived assets , and accounting for income taxes , are considered to be critical in evaluating and understanding our financial results because they involve inherently uncertain matters and their application requires the most difficult and complex judgments and estimates . these are described below . for further information on our accounting policies , see note 2 to our consolidated financial statements . revenue recognition we recognize revenue at the time we transfer title to our products to our customers consistent with generally accepted accounting principles . our products are generally sold domestically on a delivered basis and as a result we do not recognize revenue until delivered to the customer with title transferring upon completion of the delivery . for our international sales , we recognize revenue upon the transfer of title as defined by standard shipping terms and conventions uniformly recognized in international trade . we recognize deferred license revenue received pursuant to our long-term distribution agreement with baxter based on the proportion of product shipments to baxter in each period to total expected sales volume for the term of the agreement . we also recognize delivery services and other administrative services provided under the distribution agreement as revenue at the time the services are provided . allowance for doubtful accounts accounts receivable are stated at invoice amounts . the carrying amount of trade accounts receivable is reduced by an allowance for doubtful accounts that reflects our best estimate of accounts 37 that may not be collected . we review outstanding trade account receivable balances and based on our assessment of expected collections , we estimate the portion , if any , of the balance that may not be collected as well as a general valuation allowance for other accounts receivable based primarily on historical experience . all accounts or portions thereof deemed to be uncollectible are written off to the allowance for doubtful accounts . if we underestimate the allowance , we would incur a current period expense which could have a material adverse effect on earnings . share based compensation we measure the cost of employee services received in exchange for equity awards , including stock options , based on the grant date fair value of the awards in accordance with asc 718-10 , compensationstock compensation . the cost of equity based compensation is recognized as compensation expense over the vesting period of the awards . we estimate the fair value of compensation involving stock options utilizing the black-scholes option pricing model . this model requires the input of several factors such as the expected option term , expected volatility of our stock price over the expected option term , and an expected forfeiture rate , and is subject to various assumptions . we believe the valuation methodology is appropriate for estimating the fair value of stock options we grant to employees and directors which are subject to asc 718-10 requirements . these amounts are estimates and thus may not be reflective of actual future results or amounts ultimately realized by recipients of these grants . impairments of long-lived assets we account for impairment of long-lived assets , which include property and equipment , amortizable and non-amortizable intangible assets and goodwill , in accordance with authoritative accounting pronouncements . an impairment review is performed annually or whenever a change in condition occurs which indicates that the carrying amounts of assets may not be recoverable . such changes may include changes in our business strategies and plans , changes to our customer contracts , changes to our product lines and changes in our operating practices . we use a variety of factors to assess the realizable value of long-lived assets depending on their nature and use . goodwill is not amortized ; however , it must be tested for impairment at least annually . the goodwill impairment analysis is based on the fair market value of our common shares . amortization continues to be recorded for other intangible assets with definite lives over the estimated useful lives . intangible assets subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable based on future cash flows . if we determine that goodwill has been impaired , the change in value will be accounted for as a current period expense and could have a material adverse effect on earnings . accounting for income taxes we estimate our income tax provision to recognize our tax expense and our deferred tax liabilities and assets for future tax consequences of events that have been recognized in our financial statements using current enacted tax laws . deferred tax assets must be assessed based upon the likelihood of recoverability from future taxable income and to the extent that recovery is not likely , a valuation allowance is established . the allowance is regularly reviewed and updated for changes in circumstances that would cause a change in judgment about whether the related deferred tax asset may be realized . these calculations and assessments involve complex estimates and judgments because the ultimate tax outcome can be uncertain and future events unpredictable . if we determine that the deferred tax asset will be realized in the future , it may result in a material beneficial effect on earnings . 38 new accounting pronouncements in may 2014 , the financial accounting standards board issued accounting standards update no . 2014-09 , revenue from contracts with customers ( topic 606 ) , which will supersede the current revenue recognition requirements in topic 605 , revenue recognition . the asu is based on the principle

liquidity and capital resources we have adequate capital resources and substantial liquidity to pursue our business strategy . in addition to operating our concentrate business , our strategy is centered on developing , marketing and licensing high potential drug candidates including triferic® . we are actively selling and marketing triferic® and made our first commercial sales of triferic® late in 2015. as of december 31 , 2015 , we had current assets of $ 84.6 million and net working capital of $ 76.5 million . we have approximately $ 70.7 million in cash and investments as of december 31 , 2015. our uses of cash have primarily been for research and product development , investments in inventory to support our product launches and for operating expenses . cash flow from operations used $ 16.2 million in 2015 , which included research and development expenses of $ 5.0 million and an increase of $ 4.0 million in inventory levels . we also received $ 2.8 million from the exercise of stock options during 2015 and paid $ 2.9 million in taxes related to equity compensation in exchange for common shares retained by the company . our capital expenditures of $ 0.8 million in 2015 were approximately equivalent to our depreciation and amortization costs . we anticipate that we will increase our inventory and accounts receivable as we increase our drug product sales .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have adequate capital resources and substantial liquidity to pursue our business strategy . in addition to operating our concentrate business , our strategy is centered on developing , marketing and licensing high potential drug candidates including triferic® . we are actively selling and marketing triferic® and made our first commercial sales of triferic® late in 2015. as of december 31 , 2015 , we had current assets of $ 84.6 million and net working capital of $ 76.5 million . we have approximately $ 70.7 million in cash and investments as of december 31 , 2015. our uses of cash have primarily been for research and product development , investments in inventory to support our product launches and for operating expenses . cash flow from operations used $ 16.2 million in 2015 , which included research and development expenses of $ 5.0 million and an increase of $ 4.0 million in inventory levels . we also received $ 2.8 million from the exercise of stock options during 2015 and paid $ 2.9 million in taxes related to equity compensation in exchange for common shares retained by the company . our capital expenditures of $ 0.8 million in 2015 were approximately equivalent to our depreciation and amortization costs . we anticipate that we will increase our inventory and accounts receivable as we increase our drug product sales .
```    
 Suspicious Activity Report : in january 2015 , we received fda approval to market triferic® our lead branded drug . based on our clinical trial results , we believe triferic® has the potential to capture significant market share due to its unique attributes and clinical benefits , including savings on nursing administration time , potential to reduce expensive esa treatments and excellent safety profile . triferic® has a unique mode of action and has proven to be both safe and effective in iron replacement and maintenance of hemoglobin . in 2015 , we had revenue of $ 55.4 million , an increase of 2.1 % or $ 1.2 million over 2014. all of our revenue in 2014 and nearly all of our revenue in 2015 was from our dialysis concentrate business . we supply approximately 25 % of the united states domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries , primarily in the americas and the pacific rim . we obtained fda approval to market triferic® in january 2015 and commenced our marketing efforts following approval . after building sufficient inventory to support our product launch , we offered triferic® commercially in september 2015. triferic® sales and marketing efforts have been directed to providers controlling the vast majority of dialysis patients . the triferic® sales cycle is progressing in a manner and time frame consistent with the company 's prior experiences with its other product launches in the renal market . several providers have agreed to initiate pilot studies of triferic® and we anticipate these pilot programs will provide the basis for future adoption . triferic® sales in 2015 were not material . our global strategy is to out-license triferic® for key international markets . we are actively pursuing the international development and licensing of triferic® in targeted markets and regions . we recently completed a licensing agreement and product supply agreement for china . we are in discussions and negotiations regarding a number of other significant renal markets . in addition to marketing triferic® , we are working to produce sufficient inventory to begin marketing calcitriol , our generic injectable vitamin-d analogue . we are dependent upon contract manufacturing organizations to manufacture calcitriol for us . we expect to begin marketing calcitriol as soon as inventory levels are at an adequate level to ensure sufficient supply . in october 2014 , we entered into the distribution agreement with baxter , a leading global dialysis products supplier , to exclusively distribute our dialysis concentrates in the united states and certain foreign markets . the distribution agreement does not include our drug products . under the distribution agreement , we are the exclusive third party supplier of dialysis concentrates to baxter in the united states . rockwell receives a pre-defined gross profit margin on its products sold through baxter which adjusts each year over the ten year term of the agreement and is subject to an annual true-up . baxter must achieve certain growth targets to maintain its exclusivity under the agreement . this distribution agreement relates solely to our dialysis concentrate business and excludes any future 34 drug related business . for a more detailed description of the distribution agreement , see `` item 1businessdistribution agreement with baxter . we expect the distribution relationship with baxter under the distribution agreement to have a generally positive impact on our operating profit . our operating costs are expected to decrease and operating income should improve . initially , our sales will decrease , partially offset by the portion of the $ 20 million license fee received from baxter that is being recognized as revenue over the term of the distribution agreement . going forward over time , we expect our overall domestic and global concentrate sales to increase as a result of baxter 's expanded marketing reach , coupled with the anticipated expansion of our manufacturing operations in the western united states . results of operations for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 sales in 2015 , our sales were $ 55.4 million compared to $ 54.2 million in 2014 an increase of $ 1.2 million or 2.1 % . our domestic concentrate business sales increased 4.2 % or $ 1.9 million in 2015 compared to 2014. we launched triferic® in late september 2015 and our net sales of triferic® were $ 0.2 million for 2015. our international concentrate sales increased 1.3 % or $ 0.1 million in 2015 over 2014. our net revenue from third party contract manufacturing decreased $ 1.0 million in 2015 compared to 2014 following cessation of contract manufacturing for a certain non-hemodialysis customer . as a result of our distribution agreement with baxter , all domestic customer contracts for concentrate products that permitted assignment to baxter without consent have been assigned to baxter throughout 2015. baxter subsequently began to invoice those customers following assignment . our 2015 sales largely reflect the lower distributor prices paid by baxter , such that our sales are lower on those accounts billed by baxter than they were historically . our 2015 sales were favorably impacted by the recognition of deferred license revenue under the distribution agreement of $ 2.1 million in 2015 compared to $ 0.5 million in 2014. gross profit our gross profit was $ 8.9 million in 2015 , an increase of $ 0.4 million or 4.6 % compared to 2014. gross profit margins were 16.1 % in 2015 compared to 15.8 % in 2014. gross profit was favorably impacted by recognition of deferred license revenue under the distribution agreement of $ 2.1 million in 2015 compared to $ 0.5 million in 2014. gross profit was negativelyimpacted by lower sales on those accounts billed by baxter following assumption of billing by baxter . story_separator_special_tag changes in estimates are reflected in our financial statements in the period of change based upon on-going actual experience , trends , or subsequent realization depending on the nature and predictability of the estimates and contingencies . interim changes in estimates are generally applied prospectively within annual periods . certain accounting estimates , including those concerning revenue recognition , allowance for doubtful accounts , impairments of long-lived assets , and accounting for income taxes , are considered to be critical in evaluating and understanding our financial results because they involve inherently uncertain matters and their application requires the most difficult and complex judgments and estimates . these are described below . for further information on our accounting policies , see note 2 to our consolidated financial statements . revenue recognition we recognize revenue at the time we transfer title to our products to our customers consistent with generally accepted accounting principles . our products are generally sold domestically on a delivered basis and as a result we do not recognize revenue until delivered to the customer with title transferring upon completion of the delivery . for our international sales , we recognize revenue upon the transfer of title as defined by standard shipping terms and conventions uniformly recognized in international trade . we recognize deferred license revenue received pursuant to our long-term distribution agreement with baxter based on the proportion of product shipments to baxter in each period to total expected sales volume for the term of the agreement . we also recognize delivery services and other administrative services provided under the distribution agreement as revenue at the time the services are provided . allowance for doubtful accounts accounts receivable are stated at invoice amounts . the carrying amount of trade accounts receivable is reduced by an allowance for doubtful accounts that reflects our best estimate of accounts 37 that may not be collected . we review outstanding trade account receivable balances and based on our assessment of expected collections , we estimate the portion , if any , of the balance that may not be collected as well as a general valuation allowance for other accounts receivable based primarily on historical experience . all accounts or portions thereof deemed to be uncollectible are written off to the allowance for doubtful accounts . if we underestimate the allowance , we would incur a current period expense which could have a material adverse effect on earnings . share based compensation we measure the cost of employee services received in exchange for equity awards , including stock options , based on the grant date fair value of the awards in accordance with asc 718-10 , compensationstock compensation . the cost of equity based compensation is recognized as compensation expense over the vesting period of the awards . we estimate the fair value of compensation involving stock options utilizing the black-scholes option pricing model . this model requires the input of several factors such as the expected option term , expected volatility of our stock price over the expected option term , and an expected forfeiture rate , and is subject to various assumptions . we believe the valuation methodology is appropriate for estimating the fair value of stock options we grant to employees and directors which are subject to asc 718-10 requirements . these amounts are estimates and thus may not be reflective of actual future results or amounts ultimately realized by recipients of these grants . impairments of long-lived assets we account for impairment of long-lived assets , which include property and equipment , amortizable and non-amortizable intangible assets and goodwill , in accordance with authoritative accounting pronouncements . an impairment review is performed annually or whenever a change in condition occurs which indicates that the carrying amounts of assets may not be recoverable . such changes may include changes in our business strategies and plans , changes to our customer contracts , changes to our product lines and changes in our operating practices . we use a variety of factors to assess the realizable value of long-lived assets depending on their nature and use . goodwill is not amortized ; however , it must be tested for impairment at least annually . the goodwill impairment analysis is based on the fair market value of our common shares . amortization continues to be recorded for other intangible assets with definite lives over the estimated useful lives . intangible assets subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable based on future cash flows . if we determine that goodwill has been impaired , the change in value will be accounted for as a current period expense and could have a material adverse effect on earnings . accounting for income taxes we estimate our income tax provision to recognize our tax expense and our deferred tax liabilities and assets for future tax consequences of events that have been recognized in our financial statements using current enacted tax laws . deferred tax assets must be assessed based upon the likelihood of recoverability from future taxable income and to the extent that recovery is not likely , a valuation allowance is established . the allowance is regularly reviewed and updated for changes in circumstances that would cause a change in judgment about whether the related deferred tax asset may be realized . these calculations and assessments involve complex estimates and judgments because the ultimate tax outcome can be uncertain and future events unpredictable . if we determine that the deferred tax asset will be realized in the future , it may result in a material beneficial effect on earnings . 38 new accounting pronouncements in may 2014 , the financial accounting standards board issued accounting standards update no . 2014-09 , revenue from contracts with customers ( topic 606 ) , which will supersede the current revenue recognition requirements in topic 605 , revenue recognition . the asu is based on the principle

